Plasmapheresis in the treatment of patients with COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180316039112N3

Enrollment

100

Registered

2021-02-01

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus disease (covid-19). Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention group: Plasmapheresis with a dose of 40 cc per kilogram daily up to four doses.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19

Exclusion criteria

Exclusion criteria: Patient dissatisfaction with inclusion in the study

Design outcomes

Primary

Measure	Time frame
Percentage of blood oxygen saturation. Timepoint: Before and after the intervention. Method of measurement: Pulse oximetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayeb Ramim

Iran University of Medical Sciences

tayebramim@ut.ac.ir+98 21 6312 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026